prof. Filip Van den Bosch
work address
De Pintelaan 185, 0K12-IB
9000 Gent
9000 Gent
ORCID iD
0000-0002-3561-59321 – 10 of 99
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
- MR signal in the sacroiliac joint space in spondyloarthritis: a new sign
- Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
- Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis : results from a randomised phase III trial (FUTURE 1)
- Dialister as a microbial marker of disease activity in spondyloarthritis
- 2016
- Do extra-articular manifestations influence outcome in ankylosing spondylitis? : 12-year results from OASIS
- 99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients : a biodistribution and dosimetry study
- Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set : translation and cross-cultural adaptation into 15 languages
- Long-term efficiency of infliximab in patients with ankylosing spondylitis : real life data confirm the potential for dose reduction
- Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis
- Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC) : long-term extension over 7 years with focus on clinical efficacy and safety